CMO and 3PL Onboarding Checklist for DSCSA Data Exchange

Bringing a new CMO or 3PL provider into a pharmaceutical supply chain involves far more than establishing a technical connection for EPCIS data exchange. Successful onboarding requires manufacturers and their partners to align regulatory responsibilities, master data, business processes, technical configurations, and operational ownership before the first serialized shipment moves through the supply chain.

When these elements are addressed early, organizations can significantly reduce onboarding delays, improve data quality, and minimize many of the avoidable exceptions that commonly arise during live operations. Conversely, gaps in partner onboarding often surface only after production has started, resulting in failed data exchanges, investigation effort, shipment delays, and unnecessary operational disruption.

A structured onboarding process helps establish a shared operating model between trading partners from the outset. Rather than treating onboarding as a one-time IT activity, organizations should view it as a cross-functional readiness exercise involving serialization operations, supply chain, quality, regulatory, master data, and IT teams.

1. Define Roles and Responsibilities Before Exchanging Data

Successful partner onboarding begins long before the first EPCIS message is transmitted. Before configuring systems or exchanging master data, manufacturers and their partners should establish a shared understanding of each organization’s responsibilities throughout the product lifecycle.

This is particularly important because a company’s commercial relationship, such as acting as a CMO, does not by itself determine its responsibilities under DSCSA. Responsibilities depend on the activities performed and the applicable regulatory role within the supply chain. FDA guidance on identifying trading partners under DSCSA distinguishes responsibilities across manufacturers, repackagers, wholesale distributors, dispensers, and 3PLs, making role-based responsibility assignment essential. FDA: Identifying Trading Partners Under DSCSA

Defining responsibilities is equally important for operational processes that extend beyond routine data exchange. Organizations should agree on how onboarding changes will be communicated, how production or packaging changes will be managed, who is responsible for validating new products or locations, and how issues will be escalated when discrepancies or connectivity failures occur.

The GS1 US DSCSA Implementation Guideline R1.3 is also designed for CMOs, CPOs, 3PLs, and reverse logistics providers that manage serialized chain-of-custody transactions on behalf of manufacturers, wholesale distributors, and dispensers. It reinforces the importance of business process alignment and clearly defined trading partner responsibilities.

2. Verify Authorized Trading Partner Status and Regulatory Readiness

Before exchanging serialized product data, manufacturers should verify that each partner meets the applicable regulatory requirements for its role in the pharmaceutical supply chain. Under DSCSA, trading partners are responsible for conducting business only with Authorized Trading Partners.

Depending on the role performed by the organization, this may include confirming FDA registrations, state licenses, or other applicable authorization requirements. FDA’s licensure resources explain that organizations should check applicable state licensure and FDA annual reporting information for wholesale distributors and 3PLs. FDA: Check Licensure of Wholesale Drug Distributors and 3PLs

3. Establish a Shared Master Data Foundation

Once partner readiness has been confirmed, the next step is establishing a shared master data foundation. Even when regulatory requirements have been met and connectivity is in place, inconsistent master data can still result in rejected EPCIS messages, validation failures, and unnecessary investigations.

GS1 US guidance identifies standardized identifiers such as GTINs, GLNs, and SSCCs as foundational elements for interoperable traceability. FDA also notes that, while DSCSA does not require a specific location identifier such as GLN, FDA recommends the GS1 EPCIS standard for interoperable electronic data exchange under enhanced DSCSA requirements. FDA DSCSA Product Tracing FAQ

Master data governance should continue after onboarding. New products, packaging configurations, manufacturing locations, and trading partners require ongoing updates, making it essential to establish a controlled process for reviewing, approving, and communicating changes before they affect live operations.

4. Configure Technical Connectivity and Data Exchange

With partner readiness confirmed and master data aligned, the next step is establishing the technical infrastructure required for reliable EPCIS data exchange. While this phase is primarily led by IT teams, it should be completed in close collaboration with serialization operations to ensure technical configurations support agreed business processes.

Technical implementation activities typically include:

• Confirming the EPCIS version supported by each trading partner, including EPCIS 1.2, EPCIS 2.0, or both
• Agreeing on transmission method, such as AS2, SFTP, REST APIs, or a network platform
• Exchanging and validating certificates, API credentials, or other authentication mechanisms before go-live
• Defining file naming conventions, directory structures, and transmission parameters where applicable
• Configuring message acknowledgements, monitoring, and automated alert notifications
• Establishing certificate renewal and credential management procedures
• Defining technical support contacts, escalation paths, and monitoring responsibilities

These activities should be validated through end-to-end testing before production begins. Successful onboarding is achieved not only when systems can exchange EPCIS data, but also when organizations can monitor transmissions, identify failures, and resolve issues with clear support processes.

5. Align Business Processes and EPCIS Event Responsibilities

Successful interoperability depends not only on exchanging EPCIS data, but also on ensuring trading partners have a shared understanding of when, how, and by whom EPCIS events are generated. GS1 refers to this alignment of business activities and event sequencing as supply chain choreography, the agreed flow of physical product movements and their corresponding digital events.

Establishing these agreements during onboarding reduces ambiguity, improves data consistency, and streamlines investigations when discrepancies occur. The GS1 choreography addendum provides useful scenario examples for chain-of-custody event flows.

6. Validate Readiness Before Go-Live

Before exchanging live EPCIS data, manufacturers and their partners should complete end-to-end testing and confirm that the operational processes supporting data exchange are fully established. Successful onboarding is achieved not only when systems exchange messages correctly, but also when both organizations are prepared to monitor transactions, respond to exceptions, and support ongoing operations.

Conclusion

CMO and 3PL onboarding lays the foundation for successful DSCSA interoperability. The checklist presented in this article covers the key activities needed to establish regulatory, technical, and operational readiness before go-live. Organizations that invest in a structured onboarding process are better positioned to reduce implementation risk, minimize downstream exceptions, and build more reliable trading partner relationships over the long term.

The most effective onboarding programs treat partner setup as a cross-functional readiness exercise, not a one-time IT activity. When roles, ATP status, master data, connectivity, event ownership, and go-live readiness are addressed together, DSCSA data exchange becomes more stable, auditable, and operationally sustainable.